anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic low back pain (CLBP) is a prevalent and debilitating condition, leading to significant challenges to both patients and the governmental healthcare system. Non-pharmacologic interventions have received increasing attention as potential strategies to alleviate chronic low back pain and improve patient outcomes. The aim of this systematic review was to comprehensively assess the changes in blood inflammatory biomarkers after non-pharmacologic interventions for CLBP patients, thus trying to understand the complex interactions between non-pharmacologic interventions and inflammatory biomarker changes in CLBP.
METHODS: A thorough search (from January 1st, 2002 to October 5th, 2022) of PubMed, Medline (platform Web of Science), and the Cochrane Library (platform Wiley Online Library) were conducted, and inclusion criteria as well as exclusion criteria were refined to selection of the studies. Rigorous assessments of study quality were performed using RoB 2 from Cochrane or an adaptation of the Downs and Black checklist. Data synthesis includes alterations in inflammatory biomarkers after various non-pharmacologic interventions, including exercise, acupressure, neuro-emotional technique, and other modalities.
RESULTS: Thirteen primary studies were included in this systematic review, eight randomized controlled trials, one quasi-randomized trial, and four before-after studies. The interventions studied consisted of osteopathic manual treatment (one study), spinal manipulative therapy (SMT) (three studies), exercise (two studies), yoga (two studies) and acupressure (two studies), neuro-emotional technique (one study), mindfulness-based (one study) and balneotherapy study (one study). Four studies reported some changes in the inflammatory biomarkers compared to the control group. Decreased tumor necrosis factor-alpha (TNF-α) after osteopathic manual treatment (OMT), neuro-emotional technique (NET), and yoga. Decreased interleukin (IL)-1, IL-6, IL-10, and c-reactive protein (CRP) after NET, and increased IL-4 after acupressure. Another five studies found changes in inflammatory biomarkers through pre- and post-intervention comparisons, indicating improvement outcomes after intervention. Increased IL-10 after balneotherapy; decreased TNF-α, IL-1β, IL-8, Interferon-gamma, interferon-γ-induced protein 10-γ-induced protein 10 after exercise; decreased IL-6 after exercise and SMT; decreased CRP and chemokine ligand 3 after SMT.
CONCLUSION: Results suggest a moderation of inflammatory biomarkers due to different non-pharmacologic interventions for CLBP, generally resulting in decreased pro-inflammatory markers such as TNF-α and IL-6 as well as increased anti-inflammatory markers such as IL-4, thus revealing the inhibition of inflammatory processes by different non-pharmacologic interventions. However, a limited number of high-quality studies evaluating similar interventions and similar biomarkers limits the conclusion of this review.
Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
The invention relates to a medicine for treating heart and cerebrovascular diseases, which is prepared from pure Chinese medicine. The medicine is prepared from sixteen raw material medicines such as ginkgo biloba, panax notoginseng, earthworm, desertliving cistanche and epimedium herb. The medicine has good effects on coronary heart diseases, miocardial infarction, ischemic heart diseases, atrial fibrillation, premature beat, tachycardia and other heart diseases, as well as cerebral infarction, cerebral thrombosis, cerebral hemorrhage, encephalatrophy and other cerebrovascular diseases. Clinical observation shows that immediate effects can be produced if the medicine is taken in time in an early stage (within six hours) of the cerebrovascular diseases; apoplexy hemiplegia, hemiplegia, apoplexy aphasia and other symptoms can be relieved about 20 minutes after the medicine is taken; and the diseases can be radically cured if the medicine is constantly taken. The medicine can promote blood circulation to remove blood stasis, dredge blood vessels, digest atheromatous plaque, clear and activate channels and collaterals, improve microcirculation, strengthen vascular toughness, protect blood vessels, reunite tendons, activate pulse and fundamentally improve and eliminate intrinsic factors of the heart and cerebrovascular diseases, and is an ideal medicine for treating the cerebrovascular diseases. Clinical observation shows the medicine has the effective rate up to more than 98 percent and the cure rate up to 95 percent.
REMIT-DM is a feasibility pilot study that aims to show that previously published diabetes remission through early use and titration of short-term insulin therapy is possible and safe in the ambulatory diverse American population of patients with T2D, with continuous glucose level and trend information provided by CGM. We developed the algorithm based on published diabetes remission studies and include within the algorithm the CGM trend arrows to further refine insulin doses for both safety and efficacy purposes. Data captured by the CGM transmits automatically to the cloud and is accessible at any time of day by the multidisciplinary diabetes team, which includes the certified diabetes educator (CDE) and Endocrinologist. The CGM-guided insulin titration algorithm is designed to achieve euglycemia (defined as fasting CBG \< 100 mg/dL, and 2 hour post-prandial CBG \< 120 mg/dL) within 2 weeks of initiating insulin therapy, then to help maintain euglycemia for 2 weeks before discontinuing insulin entirely. Ten participants will undergo a maximum of 4 weeks of insulin therapy and will be assessed for remission afterwards to confirm enough recovery of beta cell function. (Complete remission is defined as fasting glycemia \<100 mg/dL without use of pharmacological therapy.) Afterwards, we will implement American Diabetes Association (ADA) guidelines for standard glycemic management, as necessary. We will use the data collected during this feasibility study to sharpen the CGM-guided insulin titration algorithm for creation of a T2DM remission mobile application that could then be tested and studied in a larger sample size.

The feasibility study will also take into account clinically meaningful data points e.g. the number of phone calls between the patient and the diabetes team, the patient experience, and patient satisfaction.
Although several validated wearable devices are available for detection of generalized tonic-clonic seizures, automated detection of tonic seizures is still a challenge. In this phase 1 study, we report development and validation of an artificial neural network (ANN) model for automated detection of tonic seizures with visible clinical manifestation using a wearable wristband movement sensor (accelerometer and gyroscope). The dataset prospectively recorded for this study included 70 tonic seizures from 15 patients (seven males, age 3-46 years, median = 19 years). We trained an ANN model to detect tonic seizures. The independent test dataset comprised nocturnal recordings, including 10 tonic seizures from three patients and additional (distractor) data from three subjects without seizures. The ANN model detected nocturnal tonic seizures with visible clinical manifestation with a sensitivity of 100% (95% confidence interval = 69%-100%) and with an average false alarm rate of .16/night. The mean detection latency was 14.1 s (median = 10 s), with a maximum of 47 s. These data suggest that nocturnal tonic seizures can be reliably detected with movement sensors using ANN. Large-scale, multicenter prospective (phase 3) trials are needed to provide compelling evidence for the clinical utility of this device and detection algorithm.
Unfavourable alterations of the host microbial environment, known as dysbiosis, have been identified in many canine and feline gastrointestinal (GI) diseases. As a result, normalisation of microbial composition and function has become an important therapeutic target. Given the complex and individualistic interplay between the resident microbiota, host and environment, a multimodal approach is often necessary when addressing dysbiosis in dogs and cats with GI disease. Systemic antibiotics are often empirically used to treat acute and chronic GI diseases. However, with modern genomic techniques demonstrating the profound negative effect antibiotics can have on the GI microbiota and the rapid emergence of resistant bacteria globally, there has been an increased focus on identifying antibiotic alternatives for use in small animal practice. Biotics, such as prebiotics, probiotics and synbiotics, are of growing interest due to their potential supportive effect on the microbiota. This article reviews the evidence for the use of biotics in canine and feline GI disease, highlighting how judicious use of antibiotics and targeted probiotic supplementation can enhance patient outcomes by promoting a balanced gut microbial environment.
Disclosed are a method, a device, and/or a system of efficient determination of a data entity storing healthcare data through mapped entry and/or traversal of a semantic data structure. In one embodiment, a method includes generating an entry criteria data for calculation of an entry point into one or more semantic data structure nodes. The semantic data structure is queried to receive unique identifiers of a plurality of data entities. A tag data matching the entry criteria is mapped from a term value of a medical taxonomy. The plurality of data entities includes a service profile, a professional profile, and/or a technology profile. A card data for each data entity associated with the unique identifiers is transmitted to a client device. A profile request may be generated and the semantic data structure traversed for related data entities to increase probability of connection to a solution profile applicable to the user.
A method and gene therapy agent for treating a vulnerable plaque associated with a blood vessel of a patient is disclosed. The method includes providing at least one gene therapy agent encoding at least one protein. The gene therapy agent is administered to a target cell population. The protein is expressed within the patient from a portion of the target cell population. The vulnerable plaque is modified as a result of the protein expression. The gene therapy agent includes at least one polynucleic acid encoding at least one protein. Administration of the gene therapy agent to a target cell population results in expression of the protein capable of modifying the vulnerable plaque.
When switching from pregabalin capsules or oral solution to pregabalin extended-release tablets  on the day of the switch, instruct patients to take their morning dose of pregabalin capsules or oral solution as prescribed and initiate pregabalin extended-release tablets therapy after an evening meal. 

a. 247.5 mg = 3 × 82.5 mg tablets taken once a day.   
b. 495 mg = 3 × 165 mg tablets taken once a day.   
c. 660 mg = 2 × 330 mg tablets taken once a day.
Numerous, and often largely overlapping, observational pain assessment tools have been developed specifically to assess pain in older adults with dementia under the assumption that a specialized approach is necessary to evaluate pain in this population. However, this assumption has never been tested empirically. As an empirical test of this implicit assumption, our goal was to compare existing tools for people living with dementia (with respect to psychometric properties), not only against each other, but also against a tool developed for a different population with cognitive impairments. Videos of older adults with severe dementia recorded in long-term care settings were coded for pain behaviors in the laboratory. Trained coders coded pain behaviors in video segments of older adults with dementia during a quiet baseline condition as well as during a physical examination (designed to identify painful areas), using various observational pain assessment tools. An observational measure of agitation was employed to facilitate the assessment of discriminant validity. Consistent with our expectations, all pain tools (including the tool developed for younger people with cognitive impairments) successfully differentiated between painful and nonpainful states, with large effect sizes. This was the first study to compare tools specifically developed to assess pain in people living with dementia to a tool developed for a different population. Given that all tools under study showed satisfactory psychometric properties when tested on persons with dementia, this study suggests that the assumption that different tools are necessary for different populations with cognitive impairments cannot be taken for granted. PERSPECTIVE: This article challenges an implicitly held assumption that specialized tools are needed to assess pain in different populations with cognitive impairments. Given commonalities in pain expression across populations, further research is needed to determine whether population-specific tools are needed.
1. A method for recovering copper from a copper-containing material, comprising the steps of: providing a feed stream comprising a copper-containing material; subjecting said feed stream to controlled, super-fine grinding comprises reducing the particle size of said feed stream to a P98 of less than about 25 microns; pressure leaching said inlet stream in a pressure leaching vessel at a temperature of from about 140 degree C to about 180 degree C in the presence of a surfactant to form a copper-containing solution; recovering copper from said copper-containing solution. 2. The method of claim 1, wherein said step of providing a feed stream comprising a copper-containing material comprises providing a feed stream comprising a copper sulfide ore or concentrate. 3. The method of claim 1, wherein said step of providing a feed stream comprising a copper-containing material comprises providing a feed stream comprising chalcopyrite. 4. The method of claim 1, wherein said step of subjecting said feed stream to controlled, super-fine grinding comprises reducing the particle size of said feed stream to a P98 of from about 10 to about 23 microns. 5. The method of claim 1, wherein said step of subjecting said feed stream to controlled, super-fine grinding comprises reducing the particle size of said feed stream to a P98 of from about 13 to about 15 microns. 6. The method of claim 1, wherein said step of pressure leaching said inlet stream comprises pressure leaching said inlet stream at a temperature of from about 160 to about 170 degree C. 7. The method of claim 1, wherein comprises pressure leaching said inlet stream in the presence of a surfactant selected from the group consisting of lignin derivatives, orthophenylene diamine, alkyl sulfonates, and mixtures thereof. 8. The method of claim 1, wherein comprises pressure leaching said inlet stream in the presence of calcium lignosulfonate. 9. The method of claim 1, wherein comprises pressure leaching said inlet stream in the presence of a surfactant in an amount of from about 2 to about 20 kilograms per tonne of concentrate in the inlet stream.
Acute graft-versus-host disease (GVHD) grading systems that use only clinical symptoms at treatment initiation such as the Minnesota risk identify standard and high-risk categories but lack a low-risk category suitable to minimize immunosuppressive strategies. We developed a new grading system that includes a low-risk stratum based on clinical symptoms alone and determined whether the incorporation of biomarkers would improve the model's prognostic accuracy. We randomly divided 1863 patients in the Mount Sinai Acute GVHD International Consortium (MAGIC) who were treated for GVHD into training and validation cohorts. Patients in the training cohort were divided into 14 groups based on similarity of clinical symptoms and similar nonrelapse mortality (NRM); we used a classification and regression tree (CART) algorithm to create three Manhattan risk groups that produced a significantly higher area under the receiver operating characteristic curve (AUC) for 6-month NRM than the Minnesota risk classification (0.69 vs 0.64, P = .009) in the validation cohort. We integrated serum GVHD biomarker scores with Manhattan risk using patients with available serum samples and again used a CART algorithm to establish 3 MAGIC composite scores that significantly improved prediction of NRM compared to Manhattan risk (AUC, 0.76 vs 0.70, P = .010). Each increase in MAGIC composite score also corresponded to a significant decrease in day 28 treatment response (80% vs 63% vs 30%, P < .001). We conclude that the MAGIC composite score more accurately predicts response to therapy and long-term outcomes than systems based on clinical symptoms alone and may help guide clinical decisions and trial design.
Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
Congenital anomalies of the kidney and urinary tract (CAKUT) and congenital heart disease (CHD) are the most common congenital defects and constitute a major cause of morbidity in children. Anomalies of both systems may be isolated or associated with congenital anomalies of other organ systems. Various reports support the co-occurrence of CAKUT and CHD, although the prevalence can vary. Cardiovascular anomalies occur in 11.2% to 34% of patients with CAKUT, and CAKUT occur in 5.3% to 35.8% of those with CHD. The co-occurrence of genetic factors in both CAKUT and CHD would raise common etiologies including genetics, genetic-environmental interactions, or shared molecular mechanisms and pathways such as NODAL, NOTCH, BMP, WNT, and VEGF. Studies in animal models and humans have indicated a genetic etiology for CHD and CAKUT with hundreds of genes recognized and thousands of entries, found in a catalog of human genetic disorders. There are over 80 CAKUT genes and over 100 CHD genes available for clinical testing. For example, the HNFIB gene accounts for 5% to 31% of reported cases of CAKUT. In view of the association between CAKUT and CHD, a thorough cardiac examination should be performed in patients with CAKUT, and a similar evaluation for CAKUT in the presence of CHD. This will allow early diagnosis and therapeutic intervention to improve the long- term outcome of patients affected, and test for at-risk family members. We present here evidence for an association of anomalies involving the two organ systems, and discuss possible etiologies of targeted genes, their functions, biological processes and interactions on embryogenesis.
A method of tableting comprises the compression of a mixture of at least one active agent and excipients together with liquid binder encapsulated in microparticles which disintegrate during tablet compression, thus releasing the liquid binder and causing adhesion and binding of the tablet mixture. This method enables the liquid binder to be directly released into the interstitial spaces between the active agent and excipient particles in the mixture, forming an even network of binder throughout the tablet following drying of the tablet. The liquid binder encapsulated microparticles may be made by encapsulating the binder within a relatively brittle material, such as ice or a suitable polymer, which will fracture under the pressure applied during tablet compression. The ice-encapsulated microparticles are made by passing air having a humidity content between 40% and 70% through a fluidised bed mixing chamber containing pre-frozen binder particles until a layer of ice is deposited on the surface of the individual particles. The microparticles, which preferably have a size less than 3500 microns, are stored and compressed to form the tablet at a temperature in which the ice remains frozen but the binder has thawed to a liquid. The method can be used for producing free-flowing, homogeneous tablet mixtures both above and below 0{C as required, and in turn the tablets produced are rigid and porous with high tensile strength. A variety of suitable binders and excipients are listed, and the active agent may be a pharmaceutically active agent, vitamin, flavour or a microbiological or biological material. Most preferably, the active agent is a drug for human or veterinary use.
FIELD: medicine. ^ SUBSTANCE: invention relates to chemical-pharmacological industry, namely to creation of medication for treatment of chronic kidney disease in predialystic and dialytic periods. Medication contains soy-bean isolate of "Supro" type, water-soluble fat, carbohydrate, emulsifier, food fibres, succinic and glutaminnic acids. Intake of given medication is carried out in predialytic period - in amount 1.3 g of medication per 1 kg of body weight per day, and in dialytic period - 1.7 g of medication per 1 kg of body weight per day, preliminarily dissolving it in water. ^ EFFECT: method and medication reduce infection complications and increase live quality. ^ 2 cl, 3 ex
Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
Methods are described for controlling the transbilayer distribution of ionizable lipids and proteins in vesicles. Control of the ion gradient of the exterior bathing medium in relation to that of the interior entrapped aqueous compartment of the vesicles induces migration of ionizable lipids or proteins to one or the other of the monolayers comprising the bilayer. This can result in an asymmetric distribution of the ionizable lipid or ionizable protein. The basic ionizable lipids, such as stearylamine and sphingosine, are sequestered into the inner monolayer when the liposome interior is acidic relative to the liposome exterior. Conversely, acidic ionizable lipids such as oleic acid and stearic acid are sequestered into the inner monolayer when the liposome interior is basic relative to the liposome exterior bathing solution. Likewise, phospholipids such as phosphatidylglycerol, phosphatidylinositol, and cardiolipin may also be sequestered into the inner monolayer in response to a relatively acidic exterior medium. Such vesicles may contain bioactive agents and may be administered to mammals including humans.
Participants will be immobilized using the 5 point open face immobilization mask. The thermoplastic mask immobilizes the participants head, neck and shoulders however the mask does not cover the patients anterior portion of the participants face or chest Participants randomized to this group will be monitored using intra fraction surface guided monitoring.
Patients with no ALK-resistant mutations receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, ensartinib PO QD, or pemetrexed IV over 10 minutes on day 1 with or without either cisplatin IV or carboplatin IV on day 1. ALK inhibitor cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Pemetrexed-based treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance treatment of pemetrexed may continue until disease progression or unacceptable toxicity.